Sentences with phrase «from pembrolizumab»

Dr Butler said: «Our results show that patients benefited from pembrolizumab regardless of whether or not they had been pre-treated with ipilimumab.»

Not exact matches

The FDA also expanded the approval of pembrolizumab to treat the majority of people with NSCLC who had received prior chemotherapy, greatly increasing the patient population that can benefit from the treatment.

The trial included 305 patients from 16 countries who were randomised 1:1 to pembrolizumab or chemotherapy.

«The significant improvement in overall survival with pembrolizumab was remarkable given that more than 40 % of patients crossed over from the control arm to pembrolizumab after progression of the disease,» said Reck.

Checkpoint inhibitors like ipilimumab — which has been on the market since 2011 — nivolumab, and pembrolizumab stop tumor cells from stimulating the receptors.

Reporting the results from three trials of pembrolizumab for patients with advanced melanoma, Dr Marcus Butler, a medical oncologist at the Princess Margaret Cancer Centre, Toronto, Canada, told ECCO2017 that 84 of the 1567 patients in the KEYNOTE - 001, 002 and 006 studies had advanced mucosal melanoma.

The KEYNOTE - 45 study randomised 542 patients from 29 countries between November 2014 and November 2015 to either pembrolizumab (200 mg, given intravenously once every three weeks for up to 24 months) or one of three chemotherapy options chosen by study investigators.

Once they identified this pathway, Hanks and colleagues conducted laboratory tests of a molecule that blocks melanoma cells from going stealth, enabling the immune system to mount a direct attack while also enhancing the function of current immunotherapies such as pembrolizumab and nivolumab.

Alley and his team presented data from KEYNOTE - 028, an ongoing trial involving 13 different research sites in six different countries all looking at the effect of pembrolizumab on patients with advanced malignancies, including malignant pleural mesothelioma.

Pembrolizumab blocks the action of the tumor - surface protein PD - 1, which many cancers use to hide themselves from immune system T cells.

Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania.

Aside from atezolizumab, immunotherapies in this class include avelumab (Bavencio); pembrolizumab (Keytruda); and nivolumab (Opdivo).

With the recent presentation of the data from Keynote - 024, and the recent approval of pembrolizumab for high PD - L1 expressing tumors, the landscape of lung cancer oncology will change dramatically and for the better.

Zakharia, who presented the data at the 2017 American Association for Cancer Research (AACR) Annual Meeting in Washington, DC, reveals the overall response data from the trial, toxicity data, and compares the results to historical data of pembrolizumab monotherapy from KEYNOTE - 006, which included similar patients.

Early results from an ongoing trial suggest that pembrolizumab has promising activity in untreated melanoma patients with brain metastases.

Led by Leena Gandhi, MD, PhD, associate professor of medicine and director of thoracic medical oncology, researchers from the KEYNOTE - 021 study demonstrated for the first time that combining an immune checkpoint inhibitor — in this case, pembrolizumab — with a platinum - doublet chemotherapy regimen might be more effective than chemotherapy alone as first - line treatment for advanced, non-squamous NSCLC.